Cargando…
How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial
BACKGROUND: Demonstrating treatment benefits within clinical trials in the context of rare diseases is often methodologically and practically challenging. Mixed methods research offers an approach to overcome these challenges by combining quantitative and qualitative data, thus providing a better un...
Autores principales: | Bharmal, Murtuza, Guillemin, Isabelle, Marrel, Alexia, Arnould, Benoit, Lambert, Jérémy, Hennessy, Meliessa, Fofana, Fatoumata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006962/ https://www.ncbi.nlm.nih.gov/pubmed/29914528 http://dx.doi.org/10.1186/s13023-018-0835-1 |
Ejemplares similares
-
Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma
por: Bharmal, Murtuza, et al.
Publicado: (2017) -
Correction to: Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma
por: Bharmal, Murtuza, et al.
Publicado: (2019) -
Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma
por: Bharmal, Murtuza, et al.
Publicado: (2020) -
Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial
por: Lambert, Jérémy, et al.
Publicado: (2020) -
Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences
por: Kaufman, Howard L., et al.
Publicado: (2018)